Symbols / TNYA $0.74 +6.22% Tenaya Therapeutics, Inc.
TNYA Chart
About
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Market Cap | 159.73M | Enterprise Value | 70.02M | Income | -90.60M | Sales | — | Book/sh | 0.57 | Cash/sh | 0.46 |
| Dividend Yield | — | Payout | 0.00% | Employees | 70 | IPO | — | P/E | — | Forward P/E | -1.63 |
| PEG | — | P/S | — | P/B | 1.29 | P/C | — | EV/EBITDA | -0.82 | EV/Sales | — |
| Quick Ratio | 6.51 | Current Ratio | 6.84 | Debt/Eq | 8.79 | LT Debt/Eq | — | EPS (ttm) | -0.59 | EPS next Y | -0.45 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-13 | ROA | -43.72% | ROE | -83.84% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 217.00M | Shs Float | 166.77M | Short Float | 22.22% |
| Short Ratio | 4.50 | Short Interest | — | 52W High | 2.35 | 52W Low | 0.36 | Beta | 3.00 | Avg Volume | 4.42M |
| Volume | 2.91M | Target Price | $9.00 | Recom | Strong_buy | Prev Close | $0.69 | Price | $0.74 | Change | 6.22% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-12-18 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-12-12 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-11-10 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-07 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-04-25 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | main | Canaccord Genuity | Buy → Buy | $6 |
| 2025-03-12 | main | Morgan Stanley | Overweight → Overweight | $5 |
| 2025-03-12 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-03-11 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-18 | main | Chardan Capital | Buy → Buy | $18 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- TNYA Tenaya Therapeutics Inc. shares gain over 4 percent after Q4 2025 earnings narrowly top analyst consensus estimates. - Crowd Consensus Signals - UBND thành phố Hải Phòng hu, 23 Apr 2026 01
- William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN Wed, 25 Mar 2026 08
- When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable? - Yahoo Finance Wed, 22 Apr 2026 11
- TNYA News & Events - Intellectia AI Wed, 22 Apr 2026 18
- $TNYA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- TNYA (Tenaya Therapeutics) posts slight Q4 2025 EPS beat, but shares drop 5.2 percent on soft investor sentiment. - Trending Social Stocks - UBND thành phố Hải Phòng hu, 23 Apr 2026 00
- TNYA.O Forecast — Price Prediction for 2026. Should I Buy TNYA.O? - Intellectia AI Wed, 22 Apr 2026 18
- TNYA (Tenaya Therapeutics) posts slight Q4 2025 EPS beat, but shares drop 5.2 percent on soft investor sentiment. - AI Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 11
- TNYA Should I Buy - Intellectia AI Wed, 22 Apr 2026 18
- Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance hu, 20 Nov 2025 08
- Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Yahoo Finance Fri, 20 Mar 2026 07
- TNYA.O Technical Analysis & Stock Price Forecast - Intellectia AI Wed, 22 Apr 2026 18
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Wed, 22 Apr 2026 19
- TNYA.O Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Wed, 22 Apr 2026 18
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Wed, 22 Apr 2026 18
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
93.33
-19.51%
|
115.95
-11.62%
|
131.19
+4.44%
|
125.62
|
| Research And Development |
|
68.61
-20.91%
|
86.74
-11.52%
|
98.04
+3.70%
|
94.54
|
| Selling General And Administration |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| General And Administrative Expense |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| Other Gand A |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| Total Expenses |
|
93.33
-19.51%
|
115.95
-11.62%
|
131.19
+4.44%
|
125.62
|
| Operating Income |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| Total Operating Income As Reported |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| EBITDA |
|
-84.89
+21.01%
|
-107.48
+12.27%
|
-122.51
-2.81%
|
-119.15
|
| Normalized EBITDA |
|
-84.89
+21.01%
|
-107.48
+12.27%
|
-122.51
-2.81%
|
-119.15
|
| Reconciled Depreciation |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| EBIT |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| Net Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Pretax Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Non Operating Interest Income Expense |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Net Interest Income |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Interest Income Non Operating |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Interest Income |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Other Income Expense |
|
0.05
-36.59%
|
0.08
+54.72%
|
0.05
+2550.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
0.05
-36.59%
|
0.08
+54.72%
|
0.05
+2550.00%
|
0.00
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income From Continuing Operation Net Minority Interest |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income From Continuing And Discontinued Operation |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income Continuous Operations |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Normalized Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income Common Stockholders |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Diluted EPS |
|
—
|
-1.31
+22.02%
|
-1.68
+39.13%
|
-2.76
|
| Basic EPS |
|
—
|
-1.31
+22.02%
|
-1.68
+39.13%
|
-2.76
|
| Basic Average Shares |
|
—
|
84.82
+14.96%
|
73.79
+64.61%
|
44.82
|
| Diluted Average Shares |
|
—
|
84.82
+14.96%
|
73.79
+64.61%
|
44.82
|
| Diluted NI Availto Com Stockholders |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
170.51
|
| Current Assets |
|
111.58
|
| Cash Cash Equivalents And Short Term Investments |
|
104.64
|
| Cash And Cash Equivalents |
|
45.68
|
| Other Short Term Investments |
|
58.96
|
| Receivables |
|
0.00
|
| Taxes Receivable |
|
0.00
|
| Prepaid Assets |
|
5.78
|
| Other Current Assets |
|
1.16
|
| Total Non Current Assets |
|
58.93
|
| Net PPE |
|
53.26
|
| Gross PPE |
|
77.60
|
| Accumulated Depreciation |
|
-24.34
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
20.31
|
| Construction In Progress |
|
1.73
|
| Other Properties |
|
29.95
|
| Leases |
|
25.61
|
| Investments And Advances |
|
0.00
|
| Other Non Current Assets |
|
5.68
|
| Total Liabilities Net Minority Interest |
|
31.09
|
| Current Liabilities |
|
22.73
|
| Payables And Accrued Expenses |
|
9.24
|
| Payables |
|
5.91
|
| Accounts Payable |
|
5.63
|
| Current Accrued Expenses |
|
3.33
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
8.70
|
| Total Tax Payable |
|
0.28
|
| Current Debt And Capital Lease Obligation |
|
4.32
|
| Current Capital Lease Obligation |
|
4.32
|
| Current Deferred Liabilities |
|
—
|
| Other Current Liabilities |
|
0.48
|
| Total Non Current Liabilities Net Minority Interest |
|
8.36
|
| Long Term Debt And Capital Lease Obligation |
|
8.11
|
| Long Term Capital Lease Obligation |
|
8.11
|
| Non Current Deferred Liabilities |
|
—
|
| Other Non Current Liabilities |
|
0.25
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
139.42
|
| Common Stock Equity |
|
139.42
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
68.33
|
| Ordinary Shares Number |
|
68.33
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
542.80
|
| Retained Earnings |
|
-403.28
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.11
|
| Other Equity Adjustments |
|
-0.11
|
| Total Equity Gross Minority Interest |
|
139.42
|
| Total Capitalization |
|
139.42
|
| Working Capital |
|
88.85
|
| Invested Capital |
|
139.42
|
| Total Debt |
|
12.42
|
| Capital Lease Obligations |
|
12.42
|
| Net Tangible Assets |
|
139.42
|
| Tangible Book Value |
|
139.42
|
| Available For Sale Securities |
|
—
|
| Investmentin Financial Assets |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-68.26
+24.57%
|
-90.50
+11.34%
|
-102.07
+2.25%
|
-104.42
|
| Cash Flow From Continuing Operating Activities |
|
-68.26
+24.57%
|
-90.50
+11.34%
|
-102.07
+2.25%
|
-104.42
|
| Net Income From Continuing Operations |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Depreciation Amortization Depletion |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Depreciation |
|
—
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Depreciation And Amortization |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Other Non Cash Items |
|
2.90
-23.26%
|
3.77
+12.69%
|
3.35
+35.97%
|
2.46
|
| Stock Based Compensation |
|
13.05
-20.94%
|
16.50
+7.79%
|
15.31
+33.50%
|
11.47
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-2.46
+69.03%
|
-7.93
-40.42%
|
-5.65
-565.25%
|
-0.85
|
| Change In Prepaid Assets |
|
0.55
-36.17%
|
0.86
+748.51%
|
0.10
+103.44%
|
-2.93
|
| Change In Payables And Accrued Expense |
|
-0.90
+83.14%
|
-5.33
-419.10%
|
-1.03
-117.08%
|
6.01
|
| Change In Accrued Expense |
|
0.53
+111.21%
|
-4.75
-310.33%
|
2.26
-48.11%
|
4.35
|
| Change In Payable |
|
-1.43
-146.13%
|
-0.58
+82.30%
|
-3.28
-297.71%
|
1.66
|
| Change In Account Payable |
|
-1.43
-146.13%
|
-0.58
+82.30%
|
-3.28
-297.71%
|
1.66
|
| Change In Other Current Assets |
|
0.57
-12.96%
|
0.66
+209.15%
|
-0.60
+26.26%
|
-0.81
|
| Change In Other Current Liabilities |
|
-2.68
+35.02%
|
-4.12
+0.10%
|
-4.12
-32.63%
|
-3.11
|
| Investing Cash Flow |
|
56.08
+4858.71%
|
1.13
-97.68%
|
48.72
-41.76%
|
83.65
|
| Cash Flow From Continuing Investing Activities |
|
56.08
+4858.71%
|
1.13
-97.68%
|
48.72
-41.76%
|
83.65
|
| Net PPE Purchase And Sale |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Purchase Of PPE |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Capital Expenditure |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Net Investment Purchase And Sale |
|
56.70
+2550.82%
|
2.14
-95.72%
|
49.98
-52.07%
|
104.27
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-87.07
-53.71%
|
-56.64
+59.68%
|
-140.48
|
| Sale Of Investment |
|
56.70
-36.44%
|
89.21
-16.33%
|
106.62
-56.44%
|
244.75
|
| Net Other Investing Changes |
|
—
|
0.02
+168.00%
|
-0.03
-412.50%
|
0.01
|
| Financing Cash Flow |
|
108.41
+127.03%
|
47.75
+1079.28%
|
4.05
-94.79%
|
77.77
|
| Cash Flow From Continuing Financing Activities |
|
108.41
+127.03%
|
47.75
+1079.28%
|
4.05
-94.79%
|
77.77
|
| Net Common Stock Issuance |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Common Stock Payments |
|
—
|
—
|
—
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.43
+146.00%
|
0.99
+44.72%
|
0.68
+79.47%
|
0.38
|
| Net Other Financing Charges |
|
—
|
—
|
-0.50
|
—
|
| Changes In Cash |
|
96.22
+331.19%
|
-41.62
+15.59%
|
-49.31
-186.51%
|
56.99
|
| Beginning Cash Position |
|
4.74
-89.77%
|
46.36
-51.54%
|
95.67
+147.37%
|
38.68
|
| End Cash Position |
|
100.97
+2029.19%
|
4.74
-89.77%
|
46.36
-51.54%
|
95.67
|
| Free Cash Flow |
|
-68.88
+24.74%
|
-91.53
+11.41%
|
-103.31
+17.39%
|
-125.05
|
| Amortization Of Securities |
|
0.41
+323.37%
|
-0.18
-158.41%
|
0.32
+202.61%
|
-0.31
|
| Common Stock Issuance |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Issuance Of Capital Stock |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-11 View
- 8-K2026-03-11 View
- 8-K2026-03-05 View
- 42026-02-26 View
- 42026-02-24 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-12 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 8-K2026-01-30 View
- 8-K2026-01-02 View
- 8-K2025-12-12 View
- 8-K2025-12-11 View
- 42025-11-17 View
- 42025-11-17 View
- 42025-11-17 View
- 10-Q2025-11-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|